Brainsway Ltd. BWAY

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$41.0M$31.8M$27.2M$29.7M$22.1M$23.1M$16.4M$11.1M—
Operating income —$1.4M-$5.0M-$12.7M-$5.0M-$4.8M-$8.5M-$5.1M-$6.6M—
Net income —$2.9M-$4.2M-$13.3M-$6.5M-$5.4M-$10.3M-$6.5M-$7.1M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$94.3M$63.0M$64.5M$75.7M$34.0M$38.7M$23.6M——
Total equity —$62.3M$41.6M$45.4M$57.3M$19.6M$24.2M$7.0M$12.7M$10.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001171843-26-002568.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20M 0 20M 40M 60M Revenue, FY2017: 11.1M Net income, FY2017: -7.1M Revenue, FY2018: 16.4M Net income, FY2018: -6.5M Revenue, FY2019: 23.1M Net income, FY2019: -10.3M Revenue, FY2020: 22.1M Net income, FY2020: -5.4M Revenue, FY2021: 29.7M Net income, FY2021: -6.5M Revenue, FY2022: 27.2M Net income, FY2022: -13.3M Revenue, FY2023: 31.8M Net income, FY2023: -4.2M Revenue, FY2024: 41M Net income, FY2024: 2.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $11.1M $16.4M $23.1M $22.1M $29.7M $27.2M $31.8M $41.0M —
Gross profit — — — — — — — — — —
Net income — -$7.1M -$6.5M -$10.3M -$5.4M -$6.5M -$13.3M -$4.2M $2.9M —

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%